Last $41.03 USD
Change Today +1.01 / 2.52%
Volume 146.7K
CNMD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (CNMD) Snapshot

Open
$40.98
Previous Close
$40.02
Day High
$41.83
Day Low
$39.33
52 Week High
05/19/14 - $50.47
52 Week Low
11/18/13 - $35.55
Market Cap
1.1B
Average Volume 10 Days
181.9K
EPS TTM
$1.77
Shares Outstanding
27.5M
EX-Date
09/11/14
P/E TM
23.2x
Dividend
$0.80
Dividend Yield
1.95%
Current Stock Chart for CONMED CORP (CNMD)

conmed corp (CNMD) Related Bloomberg News

View More Bloomberg News

conmed corp (CNMD) Related Businessweek News

No Related Businessweek News Found

conmed corp (CNMD) Details

CONMED Corporation provides surgical devices and equipment for minimally invasive procedures and monitoring. It offers sports medicine products, including powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; electrosurgical generators and related instruments; and 2D and 3D video systems for use in minimally invasive orthopedic and general surgeries. The company also provides patient monitoring products comprising vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; surgical suction instruments and tubing products; and IV products used in critical care areas. In addition, it offers endomechanical instrumentation products, such as trocars, clip appliers, scissors, and surgical staplers used in the minimally invasive laparoscopic and gynecological surgery. Further, the company provides gastrointestinal and pulmonary products consisting of minimally invasive diagnostic and therapeutic products, including mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and polypectomy. Its products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company operates in the United States, Canada, the United Kingdom, Japan, Australia, and internationally. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

3,600 Employees
Last Reported Date: 02/24/14
Founded in 1970

conmed corp (CNMD) Top Compensated Officers

Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $320.8K
Executive Vice President of Corporate Commerc...
Total Annual Compensation: $371.9K
Principal accounting Officer, Executive Vice ...
Total Annual Compensation: $316.9K
General Counsel and Executive Vice President ...
Total Annual Compensation: $290.6K
Compensation as of Fiscal Year 2013.

conmed corp (CNMD) Key Developments

CONMED Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reaffirms Earnings Guidance for the Full Year of 2014; Provides Tax Rate Guidance for the Fourth Quarter of 2014

CONMED Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $179,255,000 compared with $174,961,000 for the same period a year ago. Income from operations was $8,805,000 compared with $2,449,000 for the same period a year ago. Income before income taxes was $7,423,000 compared with $909,000 for the same period a year ago. Net income was $5,687,000 or $0.20 per diluted share compared with $1,972,000 or $0.07 per diluted share for the same period a year ago. Adjusted net income was $12,168,000 or $0.44 per diluted share compared with $11,097,000 or $0.40 per diluted share for the same period a year ago. Adjusted income from operations was $18,381,000 compared with $16,674,000 for the same period a year ago. EBITDA was $14,019,000 compared with $20,384,000 for the same period a year ago. Adjusted EBITDA was $31,597,000 compared with $29,859,000 for the same period a year ago. For the nine months, the company reported net sales of $559,262,000 compared with $545,052,000 for the same period a year ago. Income from operations was $40,327,000 compared with $35,697,000 for the same period a year ago. Income before income taxes was $35,933,000 compared with $31,125,000 for the same period a year ago. Net income was $25,712,000 or $0.91 per diluted share compared with $20,853,000 or $0.75 per diluted share for the same period a year ago. Net cash provided by operating activities was $53,638,000 compared with $39,529,000 for the same period a year ago. Purchases of property, plant, and equipment were $13,552,000 compared with $12,250,000 for the same period a year ago. Adjusted net income was $38,646,000 or $1.39 per diluted share compared with $35,856,000 or $1.28 per diluted share for the same period a year ago. Adjusted income from operations was $59,971,000 compared with $55,330,000 for the same period a year ago. EBITDA was $69,279,000 compared with $75,455,000 for the same period a year ago. Adjusted EBITDA was $97,717,000 compared with $94,560,000 for the same period a year ago. The company reaffirmed earnings guidance for the full year of 2014. Based on the third quarter results, the company affirms the previously provided 2014 annual revenue forecast to be in a range of $735 million - $745 million, representing a decline of 2.3% to 3.6%. Further, the company affirms the 2014 projected annual adjusted diluted net earnings per share guidance to be $1.85 - $1.95, representing an increase of 2.2% to 7.7% over 2013. The company anticipates tax rate will approximate 30% to 31% on adjusted pretax income for the fourth quarter of 2014.

CONMED Corporation to Report Q3, 2014 Results on Oct 23, 2014

CONMED Corporation announced that they will report Q3, 2014 results at 4:00 PM, US Eastern Standard Time on Oct 23, 2014

CONMED Corporation, Q3 2014 Earnings Call, Oct 23, 2014

CONMED Corporation, Q3 2014 Earnings Call, Oct 23, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNMD:US $41.03 USD +1.01

CNMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ascom Holding AG SFr.13.60 CHF +0.40
Integra LifeSciences Holdings Corp $49.72 USD +0.235
Masimo Corp $22.33 USD +0.11
NuVasive Inc $36.30 USD -0.21
Orthofix International NV $28.82 USD +0.11
View Industry Companies
 

Industry Analysis

CNMD

Industry Average

Valuation CNMD Industry Range
Price/Earnings 36.8x
Price/Sales 1.5x
Price/Book 1.9x
Price/Cash Flow 36.1x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.